{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:09:39Z","timestamp":1779253779553,"version":"3.51.4"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Imatinib, a tyrosine kinase inhibitor, is primarily used for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors (GIST). The most common adverse events include peripheral edema, mild nausea, vomiting, diarrhea, myalgia, muscle cramps, and skin rash. In patients with GIST receiving imatinib therapy, routine laboratory tests typically reveal hematologic abnormalities such as decreased hemoglobin, erythrocyte, neutrophil, and platelet counts, alongside elevated hepatic transaminase levels. However, to our knowledge, no cases of imatinib-associated hypouricemia have been reported. Here, we present a case of hypouricemia temporally associated with adjuvant imatinib therapy in a patient with intestinal GIST. This case highlights the importance for clinicians to be aware of hypouricemia as a potential adverse event during imatinib therapy.<\/jats:p>","DOI":"10.3389\/fonc.2026.1765401","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:45:23Z","timestamp":1779252323000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["First case report of hypouricemia associated with adjuvant imatinib therapy in a patient with small intestinal gastrointestinal stromal tumor"],"prefix":"10.3389","volume":"16","author":[{"given":"Juan","family":"Bu","sequence":"first","affiliation":[{"name":"Department of Medical Research and Translational Management, People\u2019s Hospital of Xinjiang Uygur Autonomous Region","place":["Urumqi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeledan","family":"Mahan","sequence":"additional","affiliation":[{"name":"Department of Medical Research and Translational Management, People\u2019s Hospital of Xinjiang Uygur Autonomous Region","place":["Urumqi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reziwanguli","family":"Yuemaier","sequence":"additional","affiliation":[{"name":"Department of Medical Research and Translational Management, People\u2019s Hospital of Xinjiang Uygur Autonomous Region","place":["Urumqi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Research and Translational Management, People\u2019s Hospital of Xinjiang Uygur Autonomous Region","place":["Urumqi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Research and Translational Management, People\u2019s Hospital of Xinjiang Uygur Autonomous Region","place":["Urumqi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-021-00254-5","article-title":"Gastrointestinal stromal tumors","volume":"7","author":"Blay","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246958","article-title":"Nationwide incidence of sarcomas and connective tissue tumors of intermediate Malignancy over four years using an expert pathology review network","volume":"16","author":"De Pinieux","year":"2021","journal-title":"PloS One"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01026-6","article-title":"The management of metastatic GIST: Current standard and investigational therapeutics","volume":"14","author":"Kelly","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-021-09961-7","article-title":"Gastrointestinal stromal tumor: a review of current and emerging therapies","volume":"40","author":"Al-Share","year":"2021","journal-title":"Cancer Metastasis Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.semdp.2006.09.001","article-title":"Gastrointestinal stromal tumors: Pathology and prognosis at different sites","volume":"23","author":"Miettinen","year":"2006","journal-title":"Semin Diagn Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199904000-00002","article-title":"Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors","volume":"23","author":"Sircar","year":"1999","journal-title":"Am J Surg Pathol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000343938","article-title":"Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors","volume":"87","author":"Saito","year":"2013","journal-title":"Digestion"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0255","article-title":"Approval summary: Imatinib mesylate in the treatment of metastatic and\/or unresectable Malignant gastrointestinal stromal tumors","volume":"14","author":"Cohen","year":"2009","journal-title":"Oncologist"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60500-6","article-title":"Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumor: a randomized, double-blind, placebo-controlled trial","volume":"373","author":"DeMatteo","year":"2009","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0498","article-title":"Association of imatinib plasma concentration and single-nucleotide polymorphisms with adverse drug reactions in patients with gastrointestinal stromal tumors","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1172910","article-title":"Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China","volume":"13","author":"Cheng","year":"2023","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s40001-022-00888-5","article-title":"Prevalence and influence of hypouricemia on cardiovascular diseases in patients with rheumatoid arthritis","volume":"27","author":"Zou","year":"2022","journal-title":"Eur J Med Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2023.107206","article-title":"Association of serum uric acid with risk of stroke in US adults: A cross-sectional study from NHANES 1999-2020","volume":"32","author":"Gao","year":"2023","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.obmed.2022.100405","article-title":"Hypouricemia is a risk factor for diabetes in Chinese adults","volume":"31","author":"Wang","year":"2022","journal-title":"Obes Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-021-00691-5","article-title":"J-shaped curve for the association between serum uric acid levels and the prevalence of blood pressure abnormalities","volume":"44","author":"Kawasoe","year":"2021","journal-title":"Hypertens Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101632","article-title":"Metabolomic and transcriptomic response to imatinib treatment of gastrointestinal stromal tumor in xenograft-bearing mice","volume":"30","author":"Macioszek","year":"2023","journal-title":"Transl Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3969\/j.issn.671-6264.2026.01.009","article-title":"Drugs and abnormal uric acid levels: analysis of the FAERS database and clinical implications","volume":"45","author":"Zhang","year":"2026","journal-title":"J Southeast Univ (Med Sci Edi)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071832","article-title":"Health-related quality of life and side effects in gastrointestinal stromal tumor (GIST) patients treated with tyrosine kinase inhibitors: A systematic review of the literature","volume":"14","author":"Van De Wal","year":"2022","journal-title":"Cancers"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2020.410","article-title":"Renal effects of uric acid: Hyperuricemia and hypouricemia","volume":"35","author":"Park","year":"2020","journal-title":"Korean J Intern Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2020.1755251","article-title":"Recent approaches to gout drug discovery: An update","volume":"15","author":"Otani","year":"2020","journal-title":"Expert Opin Drug Discov"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.343","article-title":"Effect of hypouricemic and hyperuricemic drugs on the renal urate efflux transporter, multidrug resistance protein 4","volume":"155","author":"El\u2010Sheikh","year":"2008","journal-title":"Br J Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-020-0386-7","article-title":"Impact of lesinurad and allopurinol on experimental hyperuricemia in mice: Biochemical, molecular and immunohistochemical study","volume":"21","author":"Alghamdi","year":"2020","journal-title":"BMC Pharmacol Toxicol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00518","article-title":"Identification of febuxostat as a new strong ABCG2 inhibitor: Potential applications and risks in clinical situations","volume":"7","author":"Miyata","year":"2016","journal-title":"Front Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13060899","article-title":"Modulation of urate transport by drugs","volume":"13","author":"T\u00e1trai","year":"2021","journal-title":"Pharmaceutics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate\u2013anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-3-642-14541-4_2","article-title":"In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy","volume":"201","author":"Burckhardt","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/2042098617727714","article-title":"Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations","volume":"8","author":"Guttmann","year":"2017","journal-title":"Ther Adv Drug Saf"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2007.01315.x","article-title":"Emerging therapies in the long-term management of hyperuricemia and gout","volume":"37","author":"Stamp","year":"2007","journal-title":"Internal Med J"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.842717","article-title":"OAT10\/SLC22A13 acts as a renal urate re-absorber: Clinico-genetic and functional analyses with pharmacological impacts","volume":"13","author":"Toyoda","year":"2022","journal-title":"Front Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1023\/b:card.0000015855.02485.e3","article-title":"Cardiovascular drugs and serum uric acid","volume":"17","author":"Reyes","year":"2003","journal-title":"Cardiovasc Drugs Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2010.01368.x","article-title":"Interactions of urate transporter URAT1 in human kidney with uricosuric drugs","volume":"16","author":"Shin","year":"2011","journal-title":"Nephrology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2174\/138161205774913309","article-title":"Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricemia","volume":"11","author":"Daskalopoulou","year":"2005","journal-title":"CPD"},{"key":"B36","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/08037051.2021.1996220","article-title":"Serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockers","volume":"30","author":"Zhang","year":"2021","journal-title":"Blood Pressure"},{"key":"B37","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jphs.2017.11.011","article-title":"The uricosuric effects of dihydropyridine calcium channel blockers in vivo using urate under-excretion animal models","volume":"136","author":"Hori","year":"2018","journal-title":"J Pharmacol Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajps.2019.10.002","article-title":"Pharmacologic inducers of the uric acid exporter ABCG2 as potential drugs for treatment of gouty arthritis","volume":"15","author":"Ristic","year":"2020","journal-title":"Asian J Pharm Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13670","article-title":"Uric acid and the cardio-renal effects of SGLT2 inhibitors","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.33007","article-title":"Empagliflozin attenuates hyperuricemia by upregulation of ABCG2 via AMPK\/AKT\/CREB signaling pathway in type 2 diabetic mice","volume":"16","author":"Lu","year":"2020","journal-title":"Int J Biol Sci"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1765401\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:45:29Z","timestamp":1779252329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1765401\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":40,"alternative-id":["10.3389\/fonc.2026.1765401"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1765401","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"article-number":"1765401"}}